抗TGF-β1抗体(Anti-TGF-β1, Human, Chicken-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Label	Unconjugated
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human TGF‑ beta 1Ala270-Ser390Accession # P01137
Source	Polyclonal Chicken IgY
Purification	Antigen Affinity-purified from egg yolks
Specificity	Detects TGF-beta 1/1.2 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with TGF-beta 2 is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human TGF-beta 1 (Catalog # 240-B) Recombinant Human TGF-beta 1.2 (Catalog # 304-B3)
Neutralization	Measured by its ability to neutralize TGF‑ beta 1 inhibition of IL‑4-dependent proliferation in the HT‑2 mouse T cell line [Tsang, M. et al. (1995) Cytokine 7:389]. The Neutralization Dose (ND50) is typically 5-30 ng/mL in the presence of 1 ng/mL Recombinant Human TGF‑ beta 1 and 7.5 ng/mL Recombinant Mouse IL‑4.

Neutralization

TGF‑ beta 1 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization byTGF‑ beta 1/1.2 Antibody. Recombinant Human TGF‑ beta 1 (Catalog # 240-B) inhibits Recombinant Mouse IL‑4 (Catalog # 404-ML) induced proliferation in the HT‑2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IL‑4 (7.5 ng/mL) activity elicited by Recombinant Human TGF‑ beta 1 (1 ng/mL) is neutralized (green line) by increasing concentrations of Chicken Anti-TGF‑ beta 1/1.2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-101-NA). The ND50 is typically 5-30 ng/mL.

目次に戻る

Related Product & Information

Long Name	Transforming Growth Factor beta 1 and 1.2
Entrez Gene IDs	7040 (Human); 21803 (Mouse); 59086 (Rat)
Background	TGF-beta 1/1.2
background_content	Background: TGF-beta 1/1.2 TGF-beta 1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure. TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition. Each TGF-beta isoform has some non-redundant functions; for TGF-beta 1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation, and die of overwhelming inflammation. Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin-like convertase processes the proprotein to generate an N-terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF- beta 1. Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins. Mature human TGF-beta 1 shares 100% aa identity with pig, dog and cow TGF-beta 1, and 99% aa identity with mouse, rat and horse TGF-beta 1. It demonstrates cross-species activity. TGF-beta 1 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK‑1. This complex phosphorylates and activates Smad proteins that regulate transcription. Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts.

目次に戻る

Citations

1. The Use of Platelet-Rich and Platelet-Poor Plasma to Enhance Differentiation of Skeletal Myoblasts: Implications for the Use of Autologous Blood Products for Muscle Regeneration
   Authors: O Miroshnych, WT Chang, JL Dragoo
   Am J Sports Med, 2017;45(4):945-953.
   Species: Human
   Sample Type: Platelet-Rich Plasma
   Application: IP


2. Identification of genetic loci that control mammary tumor susceptibility through the host microenvironment.
   Authors: Zhang P, Lo A, Huang Y, Huang G, Liang G, Mott J, Karpen G, Blakely E, Bissell M, Barcellos-Hoff M, Snijders A, Mao J
   Sci Rep, 2015;5(0):8919.
   Species: Mouse
   Sample Type: Whole Tissue
   Application: IHC


3. Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-beta.
   Authors: Wiener Z, Band A, Kallio P, Hogstrom J, Hyvonen V, Kaijalainen S, Ritvos O, Haglund C, Kruuna O, Robine S, Louvard D, Ben-Neriah Y, Alitalo K
   Proc Natl Acad Sci U S A, 2014;111(21):E2229-36.
   Species: Human
   Sample Type: Cell Culture Supernates
   Application: IP


4. Expression of versican V3 by arterial smooth muscle cells alters tumor growth factor beta (TGFbeta)-, epidermal growth factor (EGF)-, and nuclear factor kappaB (NFkappaB)-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion.
   Authors: Kang I, Yoon D, Braun K, Wight T
   J Biol Chem, 2014;289(22):15393-404.
   Species: Rat
   Sample Type: Whole Cells
   Application: Neut


5. IL-21 induces IL-22 production in CD4+ T cells.
   Authors: Yeste A, Mascanfroni I, Nadeau M, Burns E, Tukpah A, Santiago A, Wu C, Patel B, Kumar D, Quintana F
   Nat Commun, 2014;5(0):3753.
   Species: Mouse
   Sample Type: Whole Cells
   Application: Neut


6. Long-term gene therapy with thrombospondin 2 inhibits TGF-beta activation, inflammation and angiogenesis in chronic allograft nephropathy.
   Authors: Daniel C, Vogelbacher R, Stief A, Grigo C, Hugo C
   PLoS ONE, 2013;8(12):e83846.
   Species: Rat
   Sample Type: Whole Tissue
   Application: IHC


7. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression.
   Authors: Jelicic K, Cimbro R, Nawaz F, Huang D, Zheng X, Yang J, Lempicki R, Pascuccio M, Van Ryk D, Schwing C, Hiatt J, Okwara N, Wei D, Roby G, David A, Hwang I, Kehrl J, Arthos J, Cicala C, Fauci A
   Nat Immunol, 2013;14(12):1256-65.
   Species: Human
   Sample Type: Whole Cells
   Application: Blocking


8. Overexpression of TGF-ß 1 gene induces cell surface localized glucose-regulated protein 78-associated latency-associated peptide/TGF-ß.
   Authors: Oida T, Weiner HL
   J. Immunol., 2012;185(6):3529-35.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


9. Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues.
   Authors: Vitsky A, Waire J, Pawliuk R, Bond A, Matthews D, Lacasse E, Hawes ML, Nelson C, Richards S, Piepenhagen PA, Garman RD, Andrews L, Thurberg BL, Lonning S, Ledbetter S, Ruzek MC
   Am. J. Pathol., 2009;174(6):2137-49.
   Species: Mouse
   Sample Type: Saliva
   Application: WB


10. Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production.
    Authors: Tabata T, Kawakatsu H, Maidji E, Sakai T, Sakai K, Fang-Hoover J, Aiba M, Sheppard D, Pereira L
    Am. J. Pathol., 2008;172(4):1127-40.
    Species: Human
    Sample Type: Whole Cells
    Application: Flow

目次に戻る